|Post IPO Valuation|
|Description||Treatment for Kidney Cancer|
|Venture Round, 7/09 ||$20M|
|Venture Round, 5/10 |
Hercules Technology Growth Capital
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEOâ€™s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies.
This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec.